CRDF News and Press, Cardiff Oncology Inc. From 11/24/20

Cancer patients with K-Ras mutations comprise a large population with bleak prognosis and minimal treatment options. Recent breakthroughs in targeting only a small portion of K-Ras patients have made multibillion-dollar waves in the biotech sector. Despite failures from past compe...

Cardiff Oncology to Participate in Fireside Chat at the Piper Sandler 32nd Annual Healthcare Conference PR Newswire SAN DIEGO, Nov. 23, 2020 SAN DIEGO , Nov. 23, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF) , a clinical-stage biotechno...

Palm Beach, FL –November 9, 2020 – Much time and money has been allocated in the global breast cancer drug market, and multiple reports project continued growth in the sector. Early detection, increase in awareness, and incidence of breast cancer are some of the key trends sto...

Cardiff Oncology (CRDF): Q3 GAAP EPS of -$0.19 in-line.Revenue of $0.14M (+180.0% Y/Y) beats by $0.11M.Press Release For further details see: Cardiff Oncology EPS in-line, beats on revenue

Cardiff Oncology Announces Third Quarter 2020 Results and Highlights PR Newswire SAN DIEGO, Nov. 5, 2020 SAN DIEGO , Nov. 5, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cance...

We are initiating coverage of Cardiff Oncology (CRDF) with a "VERY BULLISH" rating at a 30 PT. We project a worldwide peak sales north of US$1bn for mCRC indication only. CRDF shares have been steadily increasing since late Q2, with catalysts including robust clinical data of Onvanser...

Palm Beach, FL –October 27, 2020 – Every year, the number of cancer-related deaths caused due to gastric cancer has been reaching to more than 800,000, as per the records of the World Health Organization. In the recent past, the number of people diagnosed with gastric cancer w...

Gainers: Align Technology (ALGN) +33%, Bio-Path Holdings (BPTH) +23%, Brainstorm Cell Therapeutics (BCLI) +13%, Beam Therapeutics (BEAM) +13%, Cardiff Oncology (CRDF) +10%.Losers: InVivo Therapeutics (NVIV) -45%, Teligent (TLGT) -27%, Apt...

New efficacy data from ongoing Phase 2 trial of Cardiff Oncology's (CRDF) onvansertib in combination with J&J's Zytiga (abiraterone) and prednisone for metastatic castration-resistant prostate cancer, achieves the primary endpoint of disease control in p...

Cardiff Oncology Presents Positive Efficacy and Biomarker Data from mCRPC Trial Demonstrating Ability of Onvansertib to Overcome Zytiga® Resistance -- Trial on track to meet prespecified criteria for success on its primary endpoint, with 31% (8/26) disease control rate in e...